Tag: Australian Market

Categories
LICs LICs

NCC With High Dividend Yields of Over 7%

Experience Co Ltd (ASX: EXP), Saunders International Ltd (ASX: SND), and Contango Asset Management Ltd are some of its current investments (ASX: CGA).

COVID-19’s effects on industrial small cap stocks have made things difficult in 2020. Despite this, since its debut in February 2013, Naos Emerging Opportunities has generated an average annual return of 10.1 percent (after expenses but before fees). The same rate is been marked in 2021 also.

The LIC has increased its dividend every year since FY13 due to which the high dividend yield appears to be safe for the next few coming years. It has a profit reserve of 32.7 cents per share, or nearly four years’ worth of dividends at the current rate.

Its current post tax NTA is $1.18 and NCC INVESTMENT PORTFOLIO PERFORMANCE SINCE INCEPTION is 13.44% marked in June 30, 2021. Even with the strong FY21 performance it is also worth adding that a number of the NCC core investments didn’t perform as expected and, in some cases, actually detracted from overall performance.

 (Source: fool.com.au)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
LICs LICs

The War of WAM on ASX! Wilson’s New LIC Hits the Share Market

The founder of WAM in charge of WAM Strategic Value is Geoff Wilson, assures investors in WAM Strategic Value’s ASX WAR prospectus that the company will focus on “finding and investing in $1 of assets for 80 cents.

The LIC intends to accomplish this by grabbing the opportunity of market mispricing like securities trading at discounts to assets or NTA (net tangible assets), corporate transactions, and dividend yield arbitrages with franking credit benefits.

WAM Strategic Value will largely be in the business of purchasing assets from other LICs and Listed Investment Trusts (LITs) for less than their true value. After all, with its $200 million+ funding, it’s likely invested in quite a bit so far. Back then, their units were trading at a 12.2 percent discount to their NTA value.

(Source: msn.com)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
ipo IPO Watch

Terms out for Clarity’s $358 million IPO

Oncology imaging technologies and medicines are the focus of Clarity. It’s working on Targeted Copper Theranostic (TCT) products, which allow copper to be utilised in the diagnosis and treatment of malignancies like prostate and breast cancer, as well as uncommon and orphan diseases like neuroblastoma, which arises from immature nerve cells in children.

It will undoubtedly be compared to Telix, the only other publicly traded radiopharmaceutical business, which has gained 38.4% year to date and has a market capitalization of $1.6 billion.

Clarity is chaired by Alan Taylor, a former Inteq consultant who handled a number of Australian listings, and is run by Colin Biggin, a former Algeta executive. Major supporters such as Australian Unity and Sydney-based investment manager Firetrail Investments joined KKR-backed GenesisCare in a $25 million pre-IPO funding round last year.

Company Profile

Clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR Technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

(Source: AFR News)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.